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Abstract: The endothelium is the inner layer of all blood vessels and it regulates hemostasis. It also
plays an active role in the regulation of the systemic inflammatory response. Systemic inflammatory
disease often results in alterations in vascular endothelium barrier function, increased permeability,
excessive leukocyte trafficking, and reactive oxygen species production, leading to organ damage.
Therapeutics targeting endothelium inflammation are urgently needed, but strong concerns regarding
the level of phenotypic heterogeneity of microvascular endothelial cells between different organs
and species have been expressed. Microvascular endothelial cell heterogeneity in different organs
and organ-specific variations in endothelial cell structure and function are regulated by intrinsic
signals that are differentially expressed across organs and species; a result of this is that neutrophil
recruitment to discrete organs may be regulated differently. In this review, we will discuss the mor-
phological and functional variations in differently originated microvascular endothelia and discuss
how these variances affect systemic function in response to inflammation. We will review emerging
in vivo and in vitro models and techniques, including microphysiological devices, proteomics, and
RNA sequencing used to study the cellular and molecular heterogeneity of endothelia from differ-
ent organs. A better understanding of microvascular endothelial cell heterogeneity will provide a
roadmap for developing novel therapeutics to target the endothelium.
Keywords: microvascular endothelial cells; heterogeneity; inflammation; endothelial barrier
permeability; leukocytes; transmigration; microphysiological systems; bMFA; sepsis; protein
kinase Cδ
1. Introduction
Structure/Function of the Endothelium
The endothelium is the innermost cell layer of blood and lymphatic vessels, from the
largest arteries to the smallest capillaries, forming a hierarchical network. Complementing
the function of the blood vasculature, the lymphatic vasculature continuously removes
excess interstitial fluid that leaks from blood vasculature and returns it into the blood
flow to maintain tissue fluid homeostasis. The lymphatic endothelium also plays a major
role in immune reactions, as reviewed elsewhere [1,2]. The blood endothelium serves as
an interface between circulation and surrounding tissue, with most intercellular commu-
nication occurring within the microvasculature composed of arterioles, capillaries, and
venules [3,4]. The endothelium is not a passive element; rather, with its secretory, synthetic,
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metabolic, immunologic, and surface expression functions, the endothelium plays a critical
role in regulating multiple physiological processes, including the control of vascular tone,
angiogenesis, and barrier permeability [5–8].
In the quiescent state, endothelial cells (EC) maintain blood fluidity, regulate vascular
permeability, and maintain limited interactions with circulating leukocytes. During acute
inflammation in pathological conditions, such as sepsis, COVID19, or radiation exposure,
a cascade of inflammatory events can alter the vascular endothelium phenotype, result-
ing in coagulation, increased barrier permeability, and leukocyte trafficking into critical
organs [3,4,9–11]. It is now well recognized that the endothelium has a critical role in the
inflammatory response and plays a key role in proinflammatory mediator production,
coagulation, leukocyte trafficking, and repair of damaged organs, making the endothelium
a critical participant in most inflammatory disease states and a potential therapeutic tar-
get. While all EC across the vasculature in different organs and in different species share
common properties, they can exhibit several phenotypes in different organs, and even
vascular beds within the same organ [3,4,6]. This EC heterogeneity is expressed as diverse
cell morphology, function, and patterns of gene expression [3,4]. Despite the complexity
of heterogeneity, EC provide a potential for targeted drug delivery to specific EC surface
markers in a variety of diseases, such as cancer and pulmonary disease [10–14]. This review
will focus on the heterogeneity of endothelial cells, with a particular emphasis on the
role of the endothelium in two types of acute inflammatory diseases which target lung
endothelia (sepsis and COVID-19), the emerging technologies to study the cellular and
molecular heterogeneity of endothelium, and novel microphysiological systems employing
both human and animal cells to increase translatability for drug development.
2. Endothelium Structure and Heterogeneity
2.1. Endothelium Heterogeneity across Organs
During development, EC originate from mesoderm precursors to form a primitive
vasculature (vasculogenesis) [15,16]. Maturation of the vasculature proceeds with the
formation of new vessels by EC sprouting and splitting through angiogenesis. In response
to epigenetic signals and microenvironmental cues, the EC differentiate into arteries, veins,
capillaries, and lymphatic vessels [3,6,17,18]. Key regulators involved in vasculogenesis
and angiogenesis are VEGF (vascular endothelial growth factor), Ang 1/2 (angiopoietin),
Tie-2, and TGF-β (transforming growth factor-β) [19]. Members of the ETS and FOX tran-
scription factor families have been implicated in early vascular development; however, the
epigenetic signals required for EC differentiation remain to be fully delineated [20]. EC are
capable of sensing and responding to the extracellular microenvironment stimuli, including
biomechanical (e.g., shear force, pressure and cyclical strain) and biochemical stimulus
(e.g., growth factors, hormones, cytokines, chemokines, nitric oxide, oxygen, and reactive
oxygen species). EC phenotypes display marked spatial and temporal organ-specific het-
erogeneity corresponding to their responses to these stimuli [6]. The development of omics
technology has revealed molecular signatures of tissue-specific microvascular endothelial
cells, as discussed in Section 4. A DNA microarray study compared the transcriptional
profiles between arterial and venous EC, and between macrovascular and microvascular
EC, demonstrating the epigenetic signature still exists after multiple passaging of EC [21].
The morphological heterogeneity of endothelium is coupled to its functional het-
erogeneity. Connected by tight junctions, the endothelia of arteries and veins form a
continuous and uninterrupted interface, surrounded by basement membranes and layers
of smooth muscle cells. In arteries and arterioles, EC align and elongate parallel to the
direction of blood flow and regulate vascular tone. In contrast, EC in veins and venules are
mostly polygonal instead of elongated in shape, lack specific orientation, and are generally
more permeable than arteries with post-capillary venules serving as the primary sites
of leukocyte extravasation during inflammation [22]. These characteristics are closely
correlated to differences in both hemodynamic environments and the functional properties
of vessels [23]. As the smallest blood vessels, with the diameter of 5 to 10 µm formed
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by a single layer of EC, capillaries are the primary site of substance exchange with the
surrounding tissues. Capillary endothelia can be classified as continuous, fenestrated,
or discontinuous (Table 1). Continuous capillaries permit the diffusion of water, small
molecules, and lipid-soluble materials, but not plasma proteins, into the surrounding
tissues and interstitial fluid. Larger molecules and nutrients pass through the endothelium
by transcytosis, a process regulated by specific transporters. Transport of macromolecules
occurs through the transcellular pathway (transcytosis, through the cell body regulated by
the cell membrane lipid bilayer) that is regulated, in part, by cytoskeleton proteins such
as actin [24–27], and is often altered by immune activation. Transendothelial electrical
resistance (TEER) is an index of current flow via the paracellular route (through the junc-
tions between cells and regulated by junctional proteins) or via the transcellular route [28].
These different regulatory mechanisms may become more prominent depending on the
phenomenon being studied. For example, we have shown that TNF-α activation had a
larger impact on BBB permeability to a 40-kDa dextran (threefold increase) compared to
TEER (23% reduction), indicating a shift from transcellular to paracellular transport [29].
Continuous capillaries exist in a more specialized state in the blood–brain barrier (BBB),
where the EC are firmly linked together by tight junctions supported by pericytes and
astrocytes, with no fenestrae and an extremely low rate of transcytosis. These special
features protect the brain from harmful substances but are also obstacles for the delivery of
therapeutic drugs into the brain [3].
Table 1. Examples of endothelial cell heterogeneity across organs.
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Fenestrated capillaries have intracellular pores with diaphragm of radi lly oriented
fibrils that penetrate the endotheliu , except in the EC of kidney glomerulus, which lacks
a diaphragm [30,31]. PV1 (plasmalemmal vesicle associated protei -1) is a major structural
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component of the diaphragm’s formation [30,32,33]. The pores not only enable the rapid
exchange of water but also permit the uptake and secretion of solutes between plasma
and interstitial fluid. Fenestrated endothelia can be found in organs with absorption,
filtration, and secretion functions, such as endocrine and exocrine glands, gastric and
intestinal mucosa, choroid plexus, glomeruli, a subpopulation of renal tubules, and in
some tumors. Though discontinuous endothelium is similar to fenestrated endothelium,
its fenestrations have a larger diameter without a diaphragm and inadequate coverage
by thinner basal lamina, which facilitates substance exchange and cell migration between
blood and interstitial fluid. Sinusoids, as the discontinuous endothelium, are located in
the liver, spleen, bone marrow, and several endocrine organs. Blood flow slows down
in sinusoids to extend the duration time, allowing extensive exchange in these organs
while the phagocytic cells patrol and engulf exogenous pathogens, damaged cells, and
debris [3,34].
The glycocalyx, which consists of proteoglycans (mainly heparan sulfate) and gly-
coproteins, covers the membrane of endothelial cells, and also exhibits organ-specific
differences. The glycocalyx regulates key vascular endothelium functions such as perme-
ability, leukocyte adhesion, shear stress transmission, and anti-inflammatory defenses [35].
Glycocalyx size correlates to vessel diameter, ranging from several 100 nm in capillaries up
to 10 µm in the carotid artery, thus directly affecting organ perfusion [36]. In the sinusoidal
capillaries of the liver, the glycocalyx is thin, whereas, in the glomerular endothelium
fenestrae, it provides an additional filtration barrier. In the continuous capillary, such as in
the lung and cremaster muscle, the glycocalyx is thicker than it is in the liver. Amongst con-
tinuous endothelium, the glycocalyx in the brain microvasculature is particularly dense and
resistant to inflammatory-induced vascular injury, and may serve a protective function [36].
The complement system is an important mediator of the immune system and is
composed of 3 separate but overlapping pathways comprised of the classical, lectin, and
alternative pathways. During inflammation or infection, complement components inter-
act with EC, producing alterations in EC permeability, cytokine/chemokine production,
leukocyte trafficking, and chemotaxis [37]. Variations in endothelial structure and function
are observed at different levels of the vascular tree, resulting in differential responses to
complement components. Comparative studies of renal and brain EC have demonstrated
differential complement-mediated activation [38], with the kidney identified as an organ
at risk for complement-induced EC damage [39]. Alternative complement pathway (AP)
activation and regulation were compared in brain microvascular endothelial cells (BMVEC)
with human glomerular vascular endothelial cells (GMVEC) to gain insight into the relative
cerebral and renal injury in atypical hemolytic uremic syndrome (aHUS) and bone marrow
transplantation-associated thrombotic microangiopathy (TA-TMA). BMVECs were more
resistant to TNF-mediated AP activation than GMVECs [38]. Additionally, under both
control and TNF-activated conditions, production of AP regulatory proteins was decreased
in GMVECs compared to BMVECS, and they act to suppress the generation of C3a and C5a,
which function as pro-inflammatory polypeptides (anaphylatoxins). These results suggest
a mechanism of increased susceptibility of the kidneys and relative resistance of the brain
to AP-mediated injury in aHUS and (TA-TMA) TA-TMA [38]. However, the differences in
complement regulation in individual vascular beds are not completely understood [39].
2.2. Endothelium Heterogeneity across Species
Several studies have shown a number of differences and similarities in EC between
different species [40–44]. These studies are important, as therapeutics for many diseases
are often developed in animal models before clinical trials. However, there are concerns
regarding the level of agreement between animal models and human diseases [45,46], and
responses in mouse models often poorly correlate with the human conditions [46].
In vitro model cell systems have been used by several groups to investigate EC species
differences [47,48]. Using a novel biomimetic microphysiological system (see description
in Section 4.3), we examined human and mouse lung microvascular EC (HLMVEC and
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MLMVEC, respectively) under physiologically relevant flow conditions [47]. While a
number of parameters were similar in the lung EC of mice and humans, significant differ-
ences were observed in microfilament alignment, TEER, and EC barrier permeability in
response to inflammatory conditions, indicating differences in EC barrier function. On EC,
selectins are important for leukocyte rolling, while adhesion molecules, such as ICAM-1
(intercellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1), are
important for leukocyte transendothelial migration. In response to TNF, both HLMVEC
and MLMVEC increased expression of E-selectin and VCAM-1. Surprisingly, in contrast to
HLMVEC, ICAM-1, was not upregulated in TNF-activated MLMVEC. As ICAM-1 is an
important regulator of leukocyte migration, our studies indicate that leukocyte–endothelial
cell interaction may be regulated differently in mouse and human lung endothelia [47].
Other groups employing organ-on chip models have also demonstrated significant
species differences. A novel liver-chip model, consisting of primary hepatocytes interfaced
with liver sinusoidal EC, has shown different lipid accumulation in rat and human models
following drug treatment [48]. Furthermore, the rat model was shown to develop indicators
of liver fibrosis to a greater extent than the human model.
In addition to functional studies, protein expression studies have also been used to
examine EC species differences. For example, expression of selenoprotein isolated from
multiple different human umbilical vein endothelial cells (HUVEC) showed little variability
and was similar over eight passages, while EC isolated from pig and bovine aorta showed
significant differences in selenoprotein expression compared to human cells [49]. As
discussed in Section 4, emerging techniques and biomimetic models of endothelial cell
function will allow us to develop a clearer understanding of the significance of species
differences between human and animal EC.
3. Endothelial Cell Alterations in Acute Inflammation
3.1. Endothelium Activation in Sepsis
Sepsis is a clinical syndrome defined as life-threatening organ dysfunction caused by
a dysregulated host response to infection that can be bacterial, fungal protozoal, or viral in
origin [50]. The vascular endothelium is an active participant in the inflammatory response
during sepsis (Figure 1). During inflammatory diseases such as sepsis, pathogen-associated
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs, cellular
components released by damaged tissues) interact with pattern recognition receptors
(PRR) located on immune cells and EC, and reprogram EC from an anti-inflammatory
to a pro-inflammatory phenotype [51,52]. Signaling through PRR activates NF-κB and
other proinflammatory transcription factors, resulting in the synthesis and release of
cytokines (e.g., TNF-α and IL-1β), chemokines (e.g., IL-8 and MCP-1), and other pro-
inflammatory signaling molecules, as well as the upregulation of adhesion molecules
(e.g., VCAM-1, ICAM-1, and vascular endothelial cadherin (VE-cadherin) [53–57]. Sepsis-
induced activation of EC results in alterations in barrier permeability, increased leukocyte–
endothelial cell interaction, and induction of cell apoptosis. Adherens junction (cadherin
family) and tight junction (occludin and claudin families) molecules are downregulated in
the endothelium during sepsis [29,58–62]. Changes in barrier function are associated with
shedding of the endothelial glycocalyx [51]. Loss of EC function induced by glycocalyx
shedding in sepsis can lead to a dampening ability of EC to appropriately respond to
shear stress. Glycocalyx shedding can also lead to impairment of EC antithrombotic
fibrinolytic functions, resulting in thrombocyte adhesion and coagulation activation. As a
result, activated EC release phosphatidylserine, which amplifies disseminated intravascular
coagulation (DIC) [52,63]. The damaging of the glycocalyx also results in oxidative stress
by compromising the antioxidant effects of heparan sulfate, which suppresses oxygen free
radical production and maintains NO availability [64,65]. Following these events, there is
increased permeability of proteins, fluids, and leukocytes, resulting in interstitial leakage
or capillary leak syndrome, which could lead to organ damage.
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endothelial cells to produce cytokines and chemoattractants, which activate neutrophils to display surface molecules that
interact with adhesion molecules expressed by activated endothelium. The rolling step involves interactions of E/P-selectin
and their ligand (e.g., PSGL-1) on neutrophils, which slows down the neutrophil. The next step, firm adhesion, is mediated
by adhesion molecules of endothelium, including ICAM-1, ICAM-2, and VCAM-1, and their neutrophil ligands, β2 integrins.
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degraded, endothelial cell tight junctions are damaged, and there is increased endothelial cell apoptosis, leading to damaged
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During sepsis, an excessive number of neutrophils are recruited from blood ves-
sels into the tissue compartment, leading to tissue damage and subsequent organ failure
(Figure 1). Circulating neutrophils activated during sepsis are critical regulators of en-
dothelial function by both secretion-dependent and adhesion-dependent events, which
can damage EC, leading to organ dysfunction [66,67]. Neutrophils regulate EC through
the formation of neutrophil extracellular traps (NETs), degranulation, and the secretion of
reactive oxygen species (ROS) and reactive nitrogen species (RNS). The release of elastase,
matrix metalloproteases, and myeloperoxidase (MPO) from neutrophil granules can cleave
the protective glycocalyx, exposing the endothelial cell surface, resulting in enhanced
leukocyte adhesion, endothelial cell activation, and increased barrier permeability [66,68].
The binding of NETs to vascular endothelium also increases permeability through dis-
ruption of adherens junctions and cytoskeleton reorganization [66]. Neutrophil-derived
extracellular vesicles containing barrier disrupting cargo can also produce junctional disor-
ganization, barrier disruption, and increased permeability [66]. Thus, while neutrophils
are critical to host defense, neutrophil dysregulation in sepsis can play a critical role in the
development of EC damage, leading to multiple organ dysfunction syndrome (MODS) and
increased mortality.
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3.2. The Classical Leukocyte Recruitment Process in Sepsis
The crosstalk between leukocytes and EC is composed of a series of interactions that
orchestrate rolling, adhesion, and transmigration [55,69,70], leading to the migration of
arrested leukocytes across endothelial cells to inflamed tissues via a multi-step process
controlled by concurrent chemoattractant-dependent signals, adhesive events, and hemody-
namic shear forces [57,71–73]. Selectins and a combination of integrins/immunoglobulins,
chemokines, and chemoattractants mediate leukocyte–endothelium interactions [74]. The
classical leukocyte recruitment process involves a multistep cascade including rolling,
followed by firm adhesion and transmigration. Each step in the cascade is mediated by
interactions of cell adhesion molecules on the surface of the endothelium with leukocyte
ligands, as well as the expression of chemokines that direct the movement of leukocytes.
Binding of endothelial E-selectin and P-selectin to leukocyte carbohydrate-based ligands
initiates the rolling of leukocytes on the endothelium. Then, firm adhesion is achieved
by binding of EC adhesion molecules, including VCAM-1 and ICAM-1, to leukocyte
integrins. Leukocyte transmigration may occur between EC or through EC, known as
transcellular and paracellular migration, respectively [75,76]. Transmigration is regulated
by junctional adhesion molecules (JAM-C), VE-cadherin, and platelet endothelial adhesion
molecule (PECAM-1) [77]. Similar to permeability, leukocyte migration occurs primarily
in postcapillary venules supported by the preferential expression of E-selectin, P-selectin,
VCAM-1, and ICAM-1 in these vessels [6]. However, as a result of organ-specific EC
heterogeneity in cell structure and function, neutrophil trafficking to discrete organs may
be differentially regulated.
3.3. The Classical Rules of Leukocyte–Endothelial Interactions Do Not Apply Universally
The classical leukocyte recruitment paradigm was primarily established by studying
the microvasculature of the murine cremaster muscle [72]. However, further studies of
different organ systems have determined that EC phenotype, morphology, and gene expres-
sion vary significantly among different vascular beds, resulting in different mechanisms of
endothelial–leukocyte interactions. Leukocyte trafficking occurs primarily in postcapillary
venules but, under certain conditions, it may also occur in other segments of the vascular
tree, including large veins, arterioles, and capillaries [22]. For example, leukocyte adhesion
and transmigration in the pulmonary circulation occurs chiefly in alveolar capillaries while,
in the bronchial circulation, it occurs primarily in the post-capillary venules. Furthermore,
the involvement of rolling motion or the requirement of E-/P-selectin in neutrophil recruit-
ment seems to be dependent on the stimulus [77]. For example, leukocyte recruitment in
Streptococcus pneumoniae-induced lung inflammation does not require the involvement
of E- or P-selectin, while neutrophil recruitment in endotoxin-treated mice was dependent
on E- and L-selectin [78,79]. Mechanical trapping of neutrophils in pulmonary capillaries
may eliminate the need for rolling on the endothelium. As the diameter of the pulmonary
capillaries is smaller than that of the neutrophil, neutrophils require longer time to deform
to pass through the capillary. As a result, neutrophil transit time is prolonged, resulting in
a higher concentration of neutrophils within the pulmonary capillary, known as neutrophil
margination. Furthermore, neutrophils activated by cytokines become stiffer, contributing
to neutrophil trapping in the capillary. Therefore, neutrophil capture in the lung is medi-
ated by neutrophil deformability rather than selectin induced rolling [80,81]. However,
prolonged firm adhesion and subsequent transmigration in the lung is at least partially
dependent on ICAM-1 [82].
During liver inflammation, 80% of leukocyte adhesion occurs in the sinusoidal en-
dothelium compared to 20% in post-sinusoidal venules [83]. Similar to the lung, the
adhesion in the sinusoids is not dependent on selectins and thus rolling. However, it is
worth noting that ICAM-1 is essential for leukocyte adhesion within the sinusoids [83]. In
normal glomeruli, neutrophils and monocytes are retained in capillaries for up to several
minutes (“dwell time”). Induction of glomerular inflammation results in activation of
leukocytes and an increase in the duration of leukocyte retention in the glomerulus, which
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is shown to be Mac-1 dependent [84]. Though rolling is not required for leukocyte adhesion,
the subsequent recruitment process in the glomeruli requires P-selectin and ICAM-1, as
well as leukocytic PSGL-1 and β2-integrins [85]. However, it is noteworthy that glomeruli
EC do not express P-selectin, but utilize platelets as a source of P-selectin for leukocyte
recruitment [85].
3.4. Endothelium Activation in COVID-19
The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) [86,87]. In severe cases of COVID-19, pneumo-
nia can develop, resulting in viral sepsis. Early findings in this rapidly evolving field
indicate that EC from different organs are involved in COVID-19, including the lung [88].
Angiotensin converting enzyme 2 (ACE2), by which the SARS-CoV-2 accesses the cell,
is expressed in both lung EC and epithelial cells [89,90]. The entry of the SARS-CoV-2
virus into the cells is also mediated by other receptors including transmembrane serin
protease 2, sialic acid receptors, and extracellular matrix metalloproteinase inducers, which
are also expressed by EC [90]. There is both preclinical and clinical evidence supporting the
hypothesis that the endothelium is a key target in COVID-19 [90]. Major symptoms found
in COVID-19 patients, such as increased blood pressure, thrombosis, and pulmonary em-
bolism, suggest that the SARS-CoV-2 virus targets the endothelium and alters endothelial
function [90]. Furthermore, histopathologic features in COVID-19 suggest a complement-
mediated endotheliopathy [91], and EC abnormalities were observed in many organs such
as kidney, liver, lung, heart, and small bowel [88]. Additionally, evidence of the ACE2
expression on the vascular endothelium has led to the hypothesis that the endothelium
is infected by SARS-CoV-2, inducing injury and activating complement, thus leading to a
persistence in inflammation [92].
A major cause of morbidity and mortality of COVID-19 is the result of the development
of acute lung injury, often leading to severe acute respiratory distress syndrome (ARDS) [93].
Pulmonary EC damage is an important contributing factor to the development of ARDS [94].
Lung pathology from COVID-19 patients demonstrated erosion of of endothelial cells in
systemic venules and the presence of vasculitus, indicating strong vascular reactions [95].
In addition, there was evidence of significant neutrophil infiltration and trafficking into
the alveolar space in these patients [95]. NETs have also been reported to be enhanced in
COVID-19 patients compared to healthy controls [96]. NETS are important for pathogen
clearance but can also significantly damage EC. Thus, based on preclinical and clinical
studies, EC are thought to play a major role in the intiation and development of COVID-19,
and targeting EC may provide novel therapeutic approaches for the treatment of this
disease [94,97].
4. Emerging Techniques and Biomimetic Models to Study Endothelial Cell Function
4.1. RNA Sequencing
Emerging techniques, such as (single cell) RNA-sequencing, have facilitated the study
of EC heterogeneity. RNA sequencing uses high-throughput sequencing methods to
provide insight into the transcriptome [98,99] by revealing the differential gene expression
patterns of EC from different species, different organs, and within the same tissue. For
example, EC isolated from heart, lung, liver, and kidney have distinct expression patterns
of gene clusters regulating barrier function, angiogenic potential, and metabolic rate. The
heterogeneous organization of vasculature in various organs is characterized in part by the
differential expression of EC markers, such as PECAM-1, VE Cadherin, and von Willebrand
factor (vWF) [4]. Transcriptomics study with single cell RNA sequencing has shown a
seamless continuum of transcriptional states of endothelial cells as they transition from
arterial into capillary and then venous phenotypes (zonation), with the prevalence of BBB-
associated trans-endothelial molecular transporters in capillaries and veins highlighting
the known physiology at these vascular locations [100].
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RNA sequencing has shown that, of the 18,910 genes expressed at baseline, the number
of tissue-specific differentially expressed genes are 1692, 1052, 570 for brain, lung and heart
endothelia, respectively, indicating different organ-specific gene signatures [101]. Lung
endothelium has a high expression of genes involved in immune function such as leukocyte
cell–cell adhesion, T cell activation, leukocyte migration, and regulation of immune system
processes [101]. For example, high expression of MHC class II genes, which are responsible
for antigen presentation, is observed in lung EC, implying its immune surveillance func-
tion [102,103]. Pulmonary endothelium, together with epithelial cells, form gas exchange
units, which are in contact with the external environment and thus various external stimuli.
The high expression of immune genes ensures a rapid immune response and emphasizes
the important role of pulmonary endothelium in host defense. In accordance with the
role of BBB in securing the brain microenvironment, brain EC express high level of genes
involved in transport process [101,102]. A similar trend was found in heart EC, where
the genes regulating cardiac muscle tissue development, myofibril assembly, and cardiac
contraction were upregulated compared with EC from other organs [101].
4.2. Proteomics
The use of proteomics has provided important insight into differential expression
of proteins within different types of EC. Compared to genomics, proteomics can provide
direct insight into protein expression, allosteric regulation, alternative splicing, and dy-
namic protein–protein interactions [104,105]. Either an unbiased or targeted approach
can be used to identify proteomic changes in disease pathologies or in response to vary-
ing experimental conditions. The unbiased approach focuses on identifying hundreds
and thousands of proteins in a single analysis, while targeted proteomics requires prior
knowledge of the proteins of interest before quantification of those proteins under dif-
ferent experimental conditions [105–107]. Protein analysis is usually accomplished by
2D gel electrophoresis (2DGE) for the separation of proteins based on charge (especially
if proteins are post-translationally modified) and mass, and liquid chromatography in
combination with mass spectrometry (LC-MS). For mass spectrometry-based proteomic
analysis, matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization
(ESI) have become important tools for the ionization of biomolecules [108].
In organ/tissue-specific microvascular endothelial beds, not all omic changes are
the same especially under normal or inflammatory conditions in human or mice EC.
Although most studies of human EC proteomics have been conducted using HUVEC
cells [109,110], the use of these cells does not represent an optimal model for recapitulating
the 3D microenvironment of the microvasculature, which is significantly impacted under
inflammatory conditions. More recent studies have employed mouse models and isolated
mouse EC to examine EC heterogeneity under physiological and inflammatory conditions,
particularly in brain, heart, kidneys, liver, and lung EC [101,111–113]. These studies
demonstrated organ-specific EC have unique translatome patterns and omic signatures
under homeostatic and inflammatory conditions. For example, in brain EC, top pathways
included synapse organization, axon development, and neurotransmitter transport, while
lung EC exhibited pathways correlating with immunity (i.e., T cell activation and leukocyte
migration), as the lung is constantly exposed to inhaled pathogens. Conversely, heart EC
have pathways related to cardiac muscle development and contraction due to energetic
demands of cardiomyocytes. In summary, these murine studies demonstrate that organ-
specific EC exhibit differential transcriptomic and proteomic expression, as well as unique
cell surface markers; these are important considerations in the development of targeted
therapeutics. Thus, the microvascular EC phenotype is affected not only by its unique,
“zip code” omic signature but also by tissue microenvironment cues such as hemodynamic
forces exerted by blood flow in a 3D morphology and interactions with nearby parenchymal
cells in its microenvironment.
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4.3. The Promise of Microphysiological Systems and Their Limitations
Microphysiological systems (MPS), a terminology often used synonymously with
“organ-on-chip” and “microfluidic systems”, generally consist of an interconnected set
of 2D and 3D cell cultures in microfluidic devices which can overcome many drawbacks
of monolayer static cell culture systems by better reproducing the in vivo endothelial
microenvironment. A strength of these systems is their ability to employ animal or human
cells, which increases translatability and the potential for drug screening. MPS can serve
as in vitro models of brain, GI tract, lung, liver, and skin microvasculature, and they are
rapidly becoming the new standard for investigating vascular biology, pharmacology, and
toxicology [29,48,114–119].
Our group has developed a novel biomimetic microfluidic assay (bMFA) (Figure 2) [120],
which reproduces the topography and flow conditions of the in vivo microvascular net-
works, for studying the leukocyte–endothelial cell interaction and endothelial function
in vitro under physiologically realistic conditions (Supplementary Video). Microvascular
network morphologies obtained from in vivo animal data were digitized using a Geo-
graphic Information System approach [121] for subsequent generation of synthetic mi-
crovascular networks using soft-lithography processes to develop the bMFA [122–126]. This
microfluidic assay consists of vascular channels in communication with an extra-vascular
tissue compartment filled with chemoattractants via a porous barrier region. Our bMFA re-
solves and facilitates real-time assessment of individual steps of neutrophil–endothelial cell
interaction migration cascade in a single system, including rolling, firm arrest, spreading,
and migration of neutrophils into the extra-vascular tissue space. EC form a confluent and
complete 3D lumen in vascular channels under physiological flow (Figure 3). Neutrophils
circulate in the vascular channels and interact with EC as they do under physiological
conditions. The bMFA enables the assessment of individual steps of the entire neutrophil
adhesion cascade in a single assay, including rolling, firm adhesion, and migration into the
extravascular tissue space [47,120,123]. Neutrophil rolling and adhesion patterns to EC in
the bMFA are similar to what is detected in vivo by intravital microscopy with preferential
binding to activated EC near bifurcations [125–127]. Unlike what is observed with neu-
trophil binding to static EC monolayers, neutrophil binding is greatest in regions of low
shear rates and minimal in regions of high shear rates (shear rate > 120 1/s), demonstrating
that fluidic shear rate strongly influences neutrophil adhesion to EC [120].
Recently, additional biomimetic microphysiological systems have been developed that
reconstitute the critical functional alveolar–capillary interface of the human lung by co-
culture of pulmonary microvascular EC and epithelial cells subjected to cyclic mechanical
strain, which can reproduce the complex integrated organ-level responses to bacteria
and inflammatory cytokines introduced into the alveolar space, and model nanoparticle
transport from alveoli into the lung vasculature [115]. Another microphysiological system,
consisting of an air–liquid interface, with epithelial cells in the apical channel (exposed to
air) and EC under shear flow in basolateral channels (exposed to plasma and/or blood cells),
can model either small tubular airway or alveolar environments [116]. The latter system
also enables functional imaging of the interior of the airway lumen (e.g., quantitation
of cilia motion including beat frequency and mucociliary transport) and microvascular
environment in the alveolus (e.g., surfactant production and leukocyte adhesion and
migration) [116]. Similar in vitro airway models of the air–liquid interface have been used
to study alveolar repair and inhalation toxicology [128–130]. The use of human cells may fill
the gap regarding species heterogeneity between in vivo animal models and human disease.
In addition, it has been shown that alveolar epithelial cells can be derived from human-
induced pluripotent stem cells, implying the huge potential of these cells to overcome the
problem of human cell availability [129]. A BBB on-a-chip microfluidic system enables the
co-culture of brain EC with astrocytes under physiological flow conditions. The system
is able to mimic the in vivo brain microenvironmental conditions and the optically clear
microfluidic BBB on a chip allows for real-time visualization and measurements of BBB
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permeability and its dynamic interactions with leukocytes [29]. Several other microfluidic
platforms modeling BBB degenerative diseases have also been developed recently [131].
While microphysiological systems are useful for providing important insight into EC
function, like all other model systems, these have significant limitations, and the labeling
of these systems as “organ-on-chip” should not be taken literally. For example, these
systems usually include the co-culture of only a few cell types in a mostly mechanically
stiff synthetic or gel scaffold, and they usually lack other important in vivo components
such as other cell types present in the tissue and the matrix. Additional limitations include
the type of polymer for chip design, time in culture, or exposure to proper levels of shear
stress. For example, incompletely cured PDMS (the most common polymer used for chip
design) can leach out and contaminate the medium and cells within the device, especially
during long-term culture [132]. EC require exposure to shear flow to function normally and
the level of shear to which they are exposed can determine their phenotype, as well as their
morphology and function [133]. Design of microfluidic systems must include vascularized
networks to provide oxygen and nutrients to multiple cell types that are required to mimic
the in vivo microenvironment. The use of 3-D printing to create these more realistic MPS,
especially for fabrication of circulatory and pulmonary systems, has been reported [134,135].
Furthermore, the use of iPSC (induced pluripotent stem cells) for creating vascularized
organoids containing EC and pericytes that can assemble into capillary networks may
represent a novel approach for studying diseases caused by vascular dysfunction [136].
More comprehensive reviews on the advantages and limitations of microfluidic models for
various applications can be found elsewhere [132,137–139]. As with other model systems,
MPS are most useful when employed to study specific, well-designed hypotheses leveraging
the strengths of these systems.




Figure 2. The biomimetic microfluidic assay (bMFA) mimics a physiologically relevant microvascular environment, which 
is used to study neutrophil-endothelial cell interactions: (A) The bMFA includes vascular channels and tissue compart-
ment, which are connected through a 3 μm barrier region (scale bar 500 μm). (B) Microvascular network maps obtained 
in vivo are reproduced on PDMS to assemble the bMFA (scale bar 1 cm). ((A) Reproduced with permission from reference 
[127], https://pubs.acs.org/doi/10.1021/ac5018716, accessed on 25 May 2021. further permissions related to the material 
excerpted should be directed to the American Chemical Society. (B) Reproduced with permission from reference [140]). 
 
Figure 3. Endothelial cells form a complete lumen in the bMFA: (A) phase contrast images show 
endothelial cells are lined up in the direction of flow (scale bar is 100 µm). (B) Confocal micrograph 
of endothelial cells showing 3D lumen formation in the vascular channel; F-actin is labeled in green 
and nuclei is labeled in red. (Reproduced with permission from reference [120]). 
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5. Leveraging Emerging Technologies to Enhance Translatability of
Ec-Targeted Therapeutics
Animal models, particularly rodents, have been used extensively for preclinical drug
development. Unfortunately, as a result of significant species differences, the predictive
power of success in human studies is severely limited. For example, all of the ~150 drugs
that were recently developed in rodent models to treat sepsis have failed in clinical tri-
als [141,142]. A significant limitation of rodent models is their differing and sometimes
contradictory response to therapeutics compared humans [6,22,45,46,143,144]. Further,
the phenotypic heterogeneity of different types of EC may also limit therapeutic devel-
opment. This lack of clinical applicability is a significant limitation of rodent models for
screening therapeutics for efficacy and toxicity for clinical applications [22,45,46,143,144].
Therefore, there is an urgent need for the development of models that better represent the
human disease and new approaches to screen potential therapeutics. A recent NIH sepsis
report encourages the “use of discovery science, computational, as well as cell-culture
and organoid-type methods in preclinical sepsis research and organoid-type methods in
practical sepsis research” using “human clinical material” and “preclinical research end-
points that specifically align with drug discovery” [145]. The microphysiological systems
discussed in Section 4.3 can use human cells to significantly enhance translatability of
therapeutic findings from animal models. These 3D culture systems can mimic the mi-
croenvironment of different organs, are not limited to a single cell types, and can model the
communication of these multiple cell types, which is critical to organ function. In addition,
the effect of therapeutics can be tested under physiologically relevant conditions, such
as shear force for vascular modeling or mechanical stretch for lung modeling. EC have
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an important role in these microphysiological or organ-on-chip models, as they play a
critical role in organ communication with the vascular system and drug delivery. These
microphysiological systems have been used to study drug development and microvascular
physiology in vascular networks, blood–brain barrier, and lung-on-a-chip [146–148]. In
most cases, these models employ organs specific human EC to increase translatability.
We have utilized our bMFA system to test a novel therapeutic that targets lung inflam-
mation. We identified protein kinase C-delta (PKCδ) as a critical regulator of inflammation.
In a rodent model of sepsis, we demonstrated that PKCδ was activated in the lung en-
dothelium, and selective PKCδ inhibition with a specific PKCδ-TAT peptide inhibitor
attenuated neutrophil influx into the lung, decreased ICAM-1 and VCAM-1 expression,
reduced alveolar-capillary permeability, decreased pulmonary edema, and preserved lung
architecture [149–152]. These rodent studies suggest that targeting PKCδ is a potential
therapeutic strategy in sepsis for the protection of organ function through the preservation
of endothelial barrier permeability and the control of neutrophil migration. Using the
bMFA, we were able to investigate specific mechanisms or steps in neutrophil–endothelial
interactions that were regulated by PKCδ, and to ascertain whether PKCδ was a critical
regulator of the inflammatory response in human cells controlling neutrophil infiltration
across endothelia and a loss of barrier function [29,47,120].
Our studies in bMFA demonstrate that proinflammatory cytokines, such as TNF,
increase EC adhesion molecule expression and neutrophil trafficking through human
endothelial cells [47,120,140,153]. Cytokine-activated human EC treated with the PKCδ
inhibitor exhibited significantly decreased neutrophil adhesion and migration, consistent
with our in vivo observations in rodents (Figure 4) [47,120,140]. Mechanistic studies demon-
strated that PKCδ regulated expression of the adhesion molecules E-selectin, VCAM-1, and
ICAM-1 (Figure 4) [47]. PKCδ is also an important regulator of endothelial cell permeability,
and PKCδ inhibition attenuated TNF-mediated endothelial cell permeability and decreased
TEER [29,47].
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Microphysiological systems that mimic the microenvironment of the BBB show great
potential for developing and screening therapeutics for treating neuro-inflammation [29,154].
For example, we employed our novel blood–brain barrier (BBB) on a chip (B3C), which
uses primary human brain microvascular endothelial cells, to show the efficacy of the
PKCδ inhibitor for treating different types of activated EC [29]. Similar to our rodent model
of sepsis-induced brain inflammation, we demonstrated that PKCδ activation is a key
signaling event that dysregulates the structural and functional integrity of BBB, which
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leads to vascular damage and inflammation-induced tissue damage due to neutrophil
transmigration [29]. PKCδ inhibition prevented activation of human brain endothelial cells,
protected BBB structure integrity, and prevented neutrophil migration across BBB endothe-
lial cells. Our data suggest that PKCδ-TAT peptide inhibitor has therapeutic potential for
the prevention or reduction of cerebrovascular injury in sepsis-induced vascular damage.
Thus, PKCδ plays a key role in the regulation of proinflammatory signaling, controlling the
activation and recruitment of neutrophils, as well as regulating endothelial permeability,
TEER, and tight junction protein expression [29,120,149,151,152,155,156].
Other groups have employed similar microphysiological models to test the efficacy
of potential therapeutics. Vascular network models have been used to investigate drug
toxicities, the regulation of angiogenesis, and risk factors for the development of throm-
bosis [146]. A “vessel chip”, which contained a layer of confluent EC, was perfused with
human blood at physiological relevant shear stress to examine blood–endothelial cell in-
teractions [157]. This model was used to examine key risk factors for the development
of thrombosis, such as platelet aggregation, platelet–endothelial cell interaction, clot for-
mation, and markers of coagulation in response to antibodies against CD40L. Another
model of vascular endothelium examined the regulation of angiogenesis and mechanisms
involved in capillary vessel sprouting [158]. This microphysiological system was used to
screen combinations of pro- and anti-angiogenic compounds to identify key mechanisms
involved in the complex multicellular process of angiogenesis. Mimetic 3D models of
the BBB have also been used to examine neuroinflammation and the impact on brain
endothelial barrier permeability [159]. When brain microvascular endothelial cells were co-
cultured with astrocytes and pericytes to model the BBB, the addition of TNF compromised
barrier function and increased permeability, as demonstrated by decreased TEER and a
reduction in the expression of tight junction proteins. Treatment with the glucocorticoid
dexamethasone was protective, and it attenuated TNF-induced barrier permeability.
Several groups have used “lung-on-a-chip” to examine different pulmonary patholo-
gies. These models contain both endothelial and epithelial cells to mimic the capillary–
alveolar interface, often with cyclic mechanical stretching, to model lung movement during
respiration [147]. These models have been used to examine the therapeutic efficacy of
angiopoietin-1 and a transient receptor potential vanilloid 4 (TRPV4) ion channel inhibitor
on IL-2- induced pulmonary edema [160]. Other studies have examined drug toxicity of the
antitumor drug gefitinib, which targets epidermal growth factor receptor (EGFR), and the
effects of titanium oxide and zinc oxide nanoparticles on endothelial and epithelial apopto-
sis [161,162]. We recently developed a biomimetic microfluidic tumor microenvironment
(bMTM) model comprised of a co-culture of tumor and human breast tumor-associated EC
in a 3D microenvironment [163]. Using this model, we demonstrated that EC permeability
significantly increased in the presence of either tumor cell-conditioned media or tumor cells.
The magnitude of this increase in permeability was significantly higher in the presence
of metastatic breast tumor cells compared to non-metastatic ones. Thus, these emerging
microphysiological systems, employing primary human EC to increase translatability, have
significant potential in applications such as cell–cell/cell–drug carrier interaction studies
and rapid screening of novel therapeutics/drug carriers.
6. Conclusions
EC are recognized as critical mediators in the progression of systemic inflammatory
disease. Dysregulated endothelium leads to impaired functions, including upregulated
expression of adhesion molecules, proinflammatory signaling, disrupted barrier integrity,
and excessive neutrophil recruitment. However, the development of clinically relevant
therapeutics has been complicated in large part by the recognition of EC heterogeneity
between different species and different organs. The increasing utilization of emerging models
such as microphysiological systems using human cells and other analytic tools may provide
novel insights to not only better understand EC function but also to develop more clinically
relevant novel therapeutics for treating inflammatory disease.
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